CVS Health Corp.

CVS Health Corp.

CVS

$90.80

Updated: 03/11/2026, 19:57:41

Market Cap
$116.12B
Sector
Healthcare
Industry
Medical - Healthcare Plans
Country
US

No historical data available

Company Profile

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

USD
NYSE
CEO: J. David Joyner
Employees: 259,500
https://www.cvshealth.com
Asset Summaries
Latest generated summaries for CVS

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
CVS-10-k-fy2025.html4.7 MBtext/htmlENFiled 10/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 44 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.8B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$7.8B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$3.0B

FY 2024 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company identity

CVS Health Corporation (a Delaware corporation) and its subsidiaries

98%
Source evidence
“references to the terms “we,” “our” or “us” used throughout this Annual Report on Form 10-K (this “10-K”) refer to CVS Health Corporation (a Delaware corporation), together with its subsidiaries”

Disclosed operating segments

Health Care Benefits; Health Services; Pharmacy & Consumer Wellness

95%
Source evidence
“Health Care Benefits segment business, sales results and/or trends, medical cost trends, medical membership, Medicare Part D membership... Health Services segment business... Pharmacy & Consumer Wellness segment business”

U.S. federal government program revenue dependence

U.S. federal government-funded programs (Medicare, Medicaid) are a significant portion of revenues

95%
Source evidence
“Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and any disruption to funding from the U.S. federal government could adversely impact our revenues and operating results.”

Pharmacy & Consumer Wellness segment revenues 2023-2025

Total revenues $139,367M in 2025 vs $124,500M in 2024 (+11.9%); products $136,575M, services $2,792M

98%
Source evidence
“Total revenues139,367124,500116,76314,867 11.9 %7,737 6.6 %”

Pharmacy & Consumer Wellness revenue by goods/service lines

Pharmacy $115,510M (+14.7%), Front Store $21,459M (-0.3%), Other $2,398M (+4.7%) in 2025

97%
Source evidence
“Pharmacy$115,510$100,687$92,111$14,823 14.7 %$8,576 9.3 %”

Corporate/Other segment performance

Corporate/Other revenues $484M in 2025; adjusted operating loss $1,687M, up $339M (25.1%) vs 2024

95%
Source evidence
“Adjusted operating loss (1) (1,687)(1,348)(1,318)(339)(25.1)%(30)(2.3)%”

Operations and dependencies

Dependency on prescription drug manufacturers and suppliers

Substantial mail order/specialty drug supply from limited number of suppliers; some single-source dependencies; short-term cancellable contracts

97%
Source evidence
“We acquire a substantial amount of our mail order and specialty pharmacies’ prescription drug supply from a limited number of suppliers.”

Prescription drug supply and pricing risk

Drug availability, pricing and supplier risks; provider/supplier consolidation raises costs and competition

92%
Source evidence
“We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.”

Positioning and strategy

Rite Aid prescription file acquisitions

Rite Aid prescription file acquisitions contributed incremental prescription volume to 2025 growth

95%
Source evidence
“including incremental volume resulting from the Company’s Rite Aid prescription file acquisitions”

2025 capital expenditures allocation

Gross capex ~$2.8B in 2025; 77% technology/digital/strategic, 23% store, fulfillment and support facilities

96%
Source evidence
“approximately 77% of the Company’s total capital expenditures were for technology, digital and other strategic initiatives and 23% were for store, fulfillment and support facilities and equipment expansion and improvements”

GLP-1 branded drugs driving pharmacy sales

Branded GLP-1 drugs drove pharmacy same store sales growth of 18.0% in 2025

93%
Source evidence
“The increase was primarily driven by pharmacy drug mix, including branded GLP-1 drugs”

Omnicare long-term care pharmacies deconsolidation

Omnicare long-term care pharmacies deconsolidated during Q3 2025

94%
Source evidence
“through the Omnicare long-term care pharmacies prior to their deconsolidation during the third quarter of 2025”

Provider joint ventures and value-based risk-sharing arrangements

Joint ventures and value-based provider arrangements to manage medical costs and expand membership/geographies

93%
Source evidence
“We are seeking to enhance our health care provider networks by entering into joint ventures and other collaborative risk-sharing arrangements with providers.”

Risks, financing, and outlook

Pharmacy reimbursement pressure and generic introductions

Continued pharmacy reimbursement pressure and recent generic drug introductions offset pharmacy growth

94%
Source evidence
“partially offset by continued pharmacy reimbursement pressure and the impact of recent generic drug introductions”

Drivers of rising health care costs

Multiple disclosed medical cost inflation drivers including drug costs (specialty/ultra-high cost), aging demographics, labor costs, flu severity, pandemics, and extreme weather

93%
Source evidence
“A number of factors contribute to rising health care and other benefit costs, including previously uninsured members entering the health care system; Medicare members’ utilization of supplemental benefits”

Generic drug margin pressure from reimbursement declines and manufacturer consolidation

Increased generic utilization has pressured reimbursement down, reducing generic margins; consolidation of generic manufacturers may increase generic drug acquisition costs.

93%
Source evidence
“increased utilization of generic drugs (which normally yield a higher gross profit rate than equivalent brand name drugs) has resulted in pressure to decrease reimbursement payments to retail, mail order and specialty pharmacies for generic drugs, causing a reduction in our margins on sales of generic drugs”

Credit ratings as of December 31, 2025

Moody's Baa3/P-3 (Stable); S&P BBB/A-2 (Negative); Fitch BBB/F2 (Negative); long-term debt ratings investment grade

98%
Source evidence
“As of December 31, 2025, Moody’s Investor Service, Inc. has assigned the Company a long-term debt rating of “Baa3” and a commercial paper rating of “P-3” with a “Stable” outlook”

Liquidity and credit facilities as of December 31, 2025

~$8.5B cash; no commercial paper outstanding; three $2.5B back-up revolvers expiring 2028-2030; ~$1.3B FHLBB capacity

96%
Source evidence
“As of December 31, 2025, the Company had approximately $8.5 billion in cash and cash equivalents, approximately $2.8 billion of which was held by the parent company or nonrestricted subsidiaries.”

2025 premium deficiency reserves: $448M individual exchange; $471M Group Medicare Advantage

Q1 2025 PDR of $448 million (individual exchange) and Q2 2025 PDR of $471 million (Group Medicare Advantage) related to anticipated 2025 coverage year losses.

97%
Source evidence
“during the first quarter of 2025, we recorded a premium deficiency reserve of $448 million related to our individual exchange product line and during the second quarter of 2025, we recorded a premium deficiency reserve of $471 million related to our Group Medicare Advantage product line within the Health Care Benefits segment”

Minimum MLR rebate requirements

Minimum MLR rebates cap insurance margin while leaving exposure to higher medical costs

93%
Source evidence
“Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs.”

IRA redesign of Medicare Part D shifts claim liability to plans

IRA changes shift more Medicare Part D claim liability to plans, including full redesign of the standard benefit effective 2025, reducing flexibility to design competitive offerings.

93%
Source evidence
“The IRA contains significant changes to the Medicare Part D program, including changes that shift more of the claim liability to plans and away from the government, including a complete redesign of the Medicare Part D standard benefit effective in 2025, which may reduce the Company’s flexibility to design competitive offerings.”

Vertical integration regulatory risk

Potential legislation prohibiting state licensure of PBM-affiliated pharmacies

92%
Source evidence
“We may face increased regulatory risks related to our vertical integration strategy, such as legislation prohibiting state licensure of pharmacies affiliated with a PBM.”

Working Families Tax Cut Act (2025) cuts Medicaid eligibility and state funding

2025 law changes Medicaid eligibility and financing, reducing beneficiary eligibility (especially expansion populations) and state funding, impacting Medicaid benefits and payment rates.

92%
Source evidence
“The “Working Families Tax Cut Act,” formerly the “One Big Beautiful Bill Act,” of 2025 makes changes to Medicaid eligibility rules and financing which will lead to reduced eligibility for Medicaid beneficiaries, particularly expansion populations, and reduced state funding”

Health care cost forecasting risk

Premiums for Insured Health Care Benefits are priced ahead of a generally twelve-month fixed premium period; forecast errors cannot be recovered in-period

97%
Source evidence
“Premiums for our Insured Health Care Benefits products are priced in advance based on our forecasts of health care and other benefit costs during a fixed premium period, which is generally twelve months.”

MLR rebate requirements cap margin and expose to higher medical costs

Minimum MLR rebate requirements limit margin in Insured Health Care Benefits and leave exposure to higher-than-expected medical costs; repeated rebates can trigger CMS enrollment bans or contract termination.

95%
Source evidence
“If a Medicare Advantage or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS.”

Credit ratings downgrades could adversely affect business

Ratings downgrades risk tied to capital deployment, debt repayment and insurer claims paying ability

95%
Source evidence
“Downgrades in our ratings could adversely affect our businesses, operating results, cash flows and financial condition.”

Tariff and trade policy risk on imported drugs and merchandise

Imported drug/merchandise exposure to U.S. tariff and trade policy changes, including actions by the current administration

95%
Source evidence
“The current administration has imposed and may further impose, or significantly increase, tariffs on imports to the United States, which could exacerbate many of these issues.”

Capital markets and investment portfolio risk

Substantial investment portfolio supporting policy liabilities is exposed to U.S. interest rates and credit market volatility

93%
Source evidence
“we have a substantial investment portfolio that supports our policy liabilities and surplus and is comprised largely of debt securities of issuers located in the U.S.”

Provider consolidation and health systems forming health plans

Provider consolidation and health-system-sponsored plans may raise medical costs and create new competitors

93%
Source evidence
“Health systems also are increasingly forming and considering forming health plans to directly offer health insurance in competition with us, a process that has been accelerated by the ACA.”

Cybersecurity, IT and AI-related risks

Cyberattack/IT disruption risk; AI use increases exposure to cybersecurity, data privacy and regulatory risk

93%
Source evidence
“The use of AI and related technology may also increase exposure to reputational, cybersecurity, data privacy, legal, regulatory and operational risks.”

Litigation and government audits exposure

Routine class actions, qui tam actions, and government audits/investigations with potentially uninsured damages

93%
Source evidence
“We routinely are subject to litigation and other adverse legal proceedings, including class actions and qui tam actions. Many of these proceedings seek substantial damages which may not be covered by insurance.”

Drug pricing benchmark changes (AWP/WAC/AAC/NADAC) threaten PBM and Pharmacy & Consumer Wellness reimbursement

Possible replacement of AWP/WAC pricing references and adoption of AAC/NADAC-based payments (NADAC showing recent volatility) could impact reimbursement and rebate negotiation.

92%
Source evidence
“CMS also publishes the National Average Drug Acquisition Cost (“NADAC”) for certain drugs; NADAC pricing, which has exhibited recent volatility, is being adopted in an increasing number of states.”

Premium rate approval risk could compress margins or force withdrawal from products/geographies

Premium rate increases require regulatory approval; denials, reductions or delays could compress operating margins and MBRs or force withdrawal from certain states or product lines.

92%
Source evidence
“If we are unable to obtain adequate premium rates and/or premium rate increases, it could materially and adversely affect our operating margins and MBRs and our ability to earn adequate returns on Insured Health Care Benefits products in one or more states or cause us to withdraw from certain geographies and/or products.”

Federal/state audit and MLR compliance challenges underway

Federal and state auditors are challenging ACA minimum MLR compliance in Commercial business and FEHB MLR compliance; Medicare and Medicaid contracts subject to MLR audits.

92%
Source evidence
“Federal and state auditors are challenging our Commercial Health Care Benefits business’ compliance with the ACA’s minimum MLR requirements as well as our FEHB plans’ compliance with OPM’s FEHB program-specific minimum MLR requirements.”

Competitive environment across segments

Highly competitive segments; HCB product mix changes and retail/specialty pharmacy customer retention risks

90%
Source evidence
“Each of our segments operates in a highly competitive and evolving business environment.”

Credit rating downgrade risk

Adverse impact from credit rating downgrades

90%
Source evidence
“We would be adversely affected by downgrades or potential downgrades in our credit ratings, should they occur, or if we do not effectively deploy our capital.”

Medicaid encounter data challenges affect premium rates and program participation

Difficulty obtaining complete, accurate encounter data could affect Medicaid premium rates, membership assignment, and ability to bid for or continue Medicaid programs; exposure to premium withholding, sanctions and fines.

90%
Source evidence
“We have experienced challenges in obtaining complete and accurate encounter data for our Medicaid products due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format”

Medicaid state audits target PBM practices

State Medicaid agencies increasingly use audits to challenge legality of PBM practices such as guaranteed effective rate reconciliations and transmission fees; potential fines, sanctions, enrollment freezes.

90%
Source evidence
“State Medicaid agencies are also increasingly using the audit process to challenge the legality of PBM practices, such as guaranteed effective rate reconciliations with retail pharmacies and transmission fees.”

Government program funding sensitivity including shutdown and debt ceiling risk

Government customers can cancel contracts on short notice; shutdowns or debt ceiling delays could delay spending, raise rates, and hurt investment portfolio value and capital markets access.

90%
Source evidence
“An extended federal government shutdown or a delay by Congress in raising the federal government’s debt ceiling also could lead to a delay, reduction, suspension or cancellation of federal government spending and a significant increase in interest rates”

M&A and divestiture risks including regulatory approval, debt, and integration failures

Acquisitions, joint ventures, alliances and divestitures carry risks including regulatory approval, goodwill impairment, unanticipated liabilities, significant debt, credit rating impact, termination fees, and integration challenges.

90%
Source evidence
“we may incur significant debt in connection with acquisitions (whether to finance acquisitions or by assuming debt from the businesses we acquire)”

M&A and divestiture risk

Acquisitions/divestitures may be unsuccessful, dilutive or add significant debt

90%
Source evidence
“We may pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities, as well as strategic divestitures, which may be unsuccessful, cause us to assume unanticipated liabilities, disrupt our existing businesses, be dilutive or lead us to assume significant debt”

Prescription drug demand risks including FDA rulings and manufacturer behavior

Revenues may decline if prescribing or drug utilization falls due to safety/regulatory restrictions, supply issues, manufacturer program participation changes, product withdrawals, generic alternatives, or drug price inflation.

88%
Source evidence
“increased safety risk profiles or regulatory restrictions; manufacturing or other supply issues; a reduction in drug manufacturers’ participation in federal programs”

Extreme events and climate change risk

Natural disasters, extreme weather, and man-made disasters could materially affect businesses; climate change long-term effects expected to be widespread and unpredictable; insurance coverage may be insufficient.

88%
Source evidence
“In particular, the long-term effects of climate change are expected to be widespread and unpredictable.”

Material exposure graph

ACA minimum MLR rebate requirements
Regulatory Exposure

MLR floors cap margins in Commercial Insured, Medicare Advantage and Medicaid and leave the company exposed to higher-than-expected medical costs; repeated rebates trigger CMS enrollment bans/termination.

Relevance 95·Dependency 85·Confidence 95
Source evidence
“Minimum MLR rebate requirements limit the level of margin we can earn in Health Care Benefits’ Commercial Insured business.”
U.S. federal and state government programs (Medicare, Medicaid)
Revenue Exposure

Government funded businesses are highly sensitive to federal/state funding, policy, shutdown and debt ceiling risk; contracts cancellable on short notice.

Relevance 92·Dependency 88·Confidence 90
Source evidence
“Federal, state and local governments have the right to cancel or not to renew their contracts with us on short notice without cause or if funds are not available.”
U.S. federal government programs (Medicare/Medicaid)
Revenue Exposure

Federal government-funded programs account for a significant portion of revenues; funding disruption would hurt revenues and operating results.

Relevance 92·Dependency 85·Confidence 94
Source evidence
“Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues”
Prescription drugs
Supplier Dependency

Pharmacy & Consumer Wellness segment, mail order/specialty pharmacy and PBM revenues depend on relationships with prescription drug manufacturers and suppliers; termination or modification could materially adversely affect results.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“we are dependent on our relationships with prescription drug manufacturers and suppliers.”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA Part D redesign shifts claim liability to plans effective 2025, affecting the Medicare Part D product economics and offering flexibility.

Relevance 90·Dependency 80·Confidence 93
Source evidence
“a complete redesign of the Medicare Part D standard benefit effective in 2025, which may reduce the Company’s flexibility to design competitive offerings.”
Prescription drugs
Raw Material Dependency

Drug availability, pricing and safety profiles affect products purchased and sold across the pharmacy and PBM businesses.

Relevance 88·Dependency 80·Confidence 92
Source evidence
“We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.”
Working Families Tax Cut Act / One Big Beautiful Bill Act (2025)
Regulatory Exposure

2025 Medicaid eligibility/financing changes reduce enrollment and state funding, pressuring Medicaid benefits and payment rates.

Relevance 88·Dependency 75·Confidence 92
Source evidence
“makes changes to Medicaid eligibility rules and financing which will lead to reduced eligibility for Medicaid beneficiaries, particularly expansion populations, and reduced state funding”
HHS/state premium rate review
Regulatory Exposure

Rate reviews and state limits restrict ability to price for medical cost increases, ACA fees and taxes, compressing Insured Health Care Benefits margins.

Relevance 85·Dependency 75·Confidence 90
Source evidence
“Rate reviews can magnify the adverse impact on our operating margins, MBRs and operating results of increases in health care and other benefit costs, increased utilization of covered services, and ACA assessments, fees and taxes, by restricting our ability to reflect these increases and/or these assessments, fees and taxes in our pricing.”
Minimum MLR rebate requirements
Regulatory Exposure

MLR rebate rules cap insurance margin while the company remains exposed to higher-than-expected medical costs.

Relevance 85·Dependency 75·Confidence 92
Source evidence
“Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs.”
Pharmacy reimbursement pressure
Cost Driver

Continued pharmacy reimbursement pressure offset revenue growth and pressured segment margins (operating income fell as % of revenues from 4.6% to 3.5%).

Relevance 85·Dependency 70·Confidence 94
Source evidence
“partially offset by continued pharmacy reimbursement pressure and the impact of recent generic drug introductions”
False Claims Act / CMS audits
Legal Exposure

Failure to report/correct errors found in CMS audits could bring fines, civil monetary penalties, or exclusion affecting participation in Medicare Advantage, Part D and other government programs.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs”
Generic prescription drugs
Cost Driver

Generic margin compression from reduced reimbursement and manufacturer consolidation raising acquisition costs directly affects pharmacy operating results.

Relevance 82·Dependency 70·Confidence 90
Source evidence
“Consolidation within the generic drug manufacturing industry and other external factors may enhance the ability of manufacturers to sustain or increase pricing of generic drugs and diminish our ability to negotiate reduced generic drug acquisition costs.”
Branded GLP-1 drugs
Demand Driver

Pharmacy same store sales growth of 18.0% in 2025 was primarily driven by pharmacy drug mix including branded GLP-1 drugs.

Relevance 80·Dependency 55·Confidence 93
Source evidence
“The increase was primarily driven by pharmacy drug mix, including branded GLP-1 drugs, and the 8.0% increase in pharmacy same store prescription volume”
PBM-affiliated pharmacy licensure legislation
Regulatory Exposure

Vertical integration strategy could be impaired by legislation prohibiting state licensure of PBM-affiliated pharmacies.

Relevance 78·Dependency 65·Confidence 90
Source evidence
“legislation prohibiting state licensure of pharmacies affiliated with a PBM”
Prescription utilization
Demand Driver

Prescriptions filled increased 5.4% in 2025 primarily driven by increased utilization, supporting pharmacy revenue growth.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“Prescriptions filled increased 5.4% on a 30-day equivalent basis in 2025 compared to 2024 primarily driven by increased utilization”
Litigation, class actions and qui tam actions
Legal Exposure

Routine litigation including class and qui tam actions seeks substantial damages not necessarily covered by insurance.

Relevance 75·Dependency 55·Confidence 92
Source evidence
“We routinely are subject to litigation and other adverse legal proceedings, including class actions and qui tam actions.”
U.S. import tariffs
Regulatory Exposure

Significant changes in tax or trade policies, tariffs or trade relations could significantly increase costs and restrict access to suppliers of imported drugs and merchandise.

Relevance 75·Dependency 55·Confidence 92
Source evidence
“significant changes in tax or trade policies, tariffs or trade relations between the U.S. and other countries, such as the imposition of unilateral tariffs on imported products, could result in significant increases in our costs, restrict our access to suppliers”
Omnicare
Legal Exposure

$929 million of litigation charges in 2025 related to the Omnicare long-term care business; Omnicare was deconsolidated in Q3 2025.

Relevance 70·Dependency 40·Confidence 93
Source evidence
“$929 million in litigation charges recorded in 2025 related to the Omnicare long-term care business”
Rite Aid prescription files
Demand Driver

Acquisition of Rite Aid prescription files added incremental prescription volume, driving 2025 pharmacy revenue and adjusted operating income growth.

Relevance 70·Dependency 35·Confidence 92
Source evidence
“primarily driven by increased prescription volume, including incremental volume resulting from the Company’s Rite Aid prescription file acquisitions”
Health plan members / medical membership
Demand Driver

Joint ventures and risk-sharing arrangements may expand into new geographies, target new customer groups and increase membership; failure would reduce medical membership growth and competitiveness.

Relevance 65·Dependency 55·Confidence 85
Source evidence
“These arrangements also may allow us to expand into new geographies, target new customer groups, increase membership and reduce medical costs”
Provider and supplier consolidation
Competitive Exposure

Continuing consolidation among providers and suppliers may increase the company's costs and increase competition.

Relevance 65·Dependency 50·Confidence 88
Source evidence
“Continuing consolidation and integration among providers and other suppliers may increase our costs and increase competition.”
Generic drug introductions
Cost Driver

Recent generic drug introductions partially offset pharmacy revenue growth in 2025.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“partially offset by continued pharmacy reimbursement pressure and the impact of recent generic drug introductions”
Natural disasters and extreme weather events
Cost Driver

Natural disasters and extreme weather events, which may increase in frequency or intensity due to climate change, drive health care benefit costs.

Relevance 60·Dependency 45·Confidence 85
Source evidence
“natural disasters and extreme weather events (which may increase in frequency or intensity as a result of climate change)”
USD
Currency Exposure

Investment income largely driven by U.S. interest rate levels; U.S. credit market and monetary policy volatility can reduce portfolio value, net investment income and debt issuance capacity.

Relevance 55·Dependency 60·Confidence 90
Source evidence
“the income we earn from our investment portfolio is largely driven by the level of interest rates in the U.S.”
Target Corporation
Revenue Exposure

Store counts include retail drugstores and pharmacies located within Target stores.

Relevance 55·Dependency 30·Confidence 85
Source evidence
“Includes retail drugstores and pharmacies within retail chains, primarily in Target Corporation (“Target”) stores.”
Full company information
Latest profile, trading, valuation, and identifier data stored for CVS.
Share price
$90.80
Market cap
$116.12B
Exchange
NYSE
Currency
USD
CEO
J. David Joyner
Employees
259,500
IPO date
21/02/1973
Beta
0.58
Last dividend
$0.00
Day range
$88.10 – $91.09
52-week range
$69.51 – $110.68
1-day performance
2.58%
1-year performance
30.62%
Current drawdown (1Y)
-17.97%
CIK
0000064803
CUSIP
126650100
ISIN
US1266501006
Created
07/12/2025, 03:30:45
Last update
03/11/2026, 19:57:41

Track CVS Health Corp. with an AI analyst

See which prediction-market events move CVS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to CVS from your Railway `news_articles` table.

5 Low Price-to-Book Stocks That Are Worth Buying in June

Zacks Investment Research • STOCK • 12/06/2026, 12:51:13

CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research • STOCK • 12/06/2026, 12:16:03

Healthy Returns: CVS Health executives on reducing health care's biggest pain points

CNBC • STOCK • 11/06/2026, 17:18:11

Trump's Economy Hired Nearly 1 Million Healthcare Workers While Every Other Sector Lost Jobs. Here's Where to Put Your Money

24/7 Wall Street • STOCK • 10/06/2026, 10:34:22

CVS Offers A Compelling Turnaround Opportunity Not Seen In Years

Seeking Alpha • STOCK • 10/06/2026, 01:47:38

Has CVS Health (CVS) Outpaced Other Medical Stocks This Year?

Zacks Investment Research • STOCK • 08/06/2026, 12:41:25

Medicare Advantage Continues To Grow Despite Health Insurer Exits

Forbes • STOCK • 07/06/2026, 10:25:08

CVS Health (CVS) Advances While Market Declines: Some Information for Investors

Zacks Investment Research • STOCK • 05/06/2026, 20:46:21

Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet

Zacks Investment Research • STOCK • 04/06/2026, 12:31:11

Why CVS Health (CVS) is a Top Growth Stock for the Long-Term

Zacks Investment Research • STOCK • 03/06/2026, 12:45:38

Here's Why CVS Health (CVS) is a Strong Value Stock

Zacks Investment Research • STOCK • 02/06/2026, 12:41:12

CVS Health (NYSE: CVS) Maintains Overweight Rating Amid Strategic Expansions and AI Innovation

Market Data • Market Data • 01/06/2026, 14:00:34